Demcizumab
Modify Date: 2024-01-15 19:42:56
Demcizumab structure
|
Common Name | Demcizumab | ||
|---|---|---|---|---|
| CAS Number | 1243262-17-0 | Molecular Weight | 145.65 (kDa) | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of DemcizumabDemcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models[1][2][3]. |
| Name | Demcizumab |
|---|
| Description | Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
DLL4[1] |
| In Vitro | Demcizumab (0-100 μg/mL) 结合人 DLL4 但不结合鼠 DLL4，并在 FACS 结合测定中阻断 DLL4 与 Notch1 受体的结合[3]。 Demcizumab (20 μg/mL，48 小时) 降低 PDTALL 细胞中的 HES1 和 DTX1 mRNA 表达[4]。 Demcizumab (0-80 μg/mL，1 或 2 或 3 天) 促进 PDTALL13 细胞死亡和早期凋亡[4]。 Cell Viability Assay[4] Cell Line: PDTALL13 (patient-derived T-ALL 13) cell Concentration: 0, 0.5, 1, 5, 10, 20, 40, 80 μg/mL Incubation Time: 1 or 2 or 3 days Result: Dose-dependently inhibited cell viability. |
| In Vivo | Demcizumab (10 mg/kg，i.p.，每周一次) 联合 Irinotecan (7.5 mg/kg) 在 KRASWT 和 KRASMT CRC 异种移植模型中显示出显着的抗肿瘤作用[2]. Demcizumab 单独或与伊立替康 (7.5 mg/kg) 联合使用对 OMP-C8 结肠肿瘤有效[3]。 Demcizumab (20 mg/kg/周，腹腔注射) 增加注射了 PDTALL13 细胞的受辐照 NRG 小鼠的存活率[4]。 Animal Model: KRASWT and KRASMT CRC xenografts[2] Dosage: 10 mg/kg, together with Irinotecan (HY-16562) (7.5 mg/kg) Administration: Intraperitoneal injection (i.p.), once a week Result: Resulted in tumor regression at day 20. |
| References |
| Molecular Weight | 145.65 (kDa) |
|---|